Table 4.
Summary of Clinical trials of FGFR inhibitors.
| Agent | Target | Phase | Enrolled patients | Treatment arms | Results | NCT number | Reference |
|---|---|---|---|---|---|---|---|
| AZD4547 | FGFR1/2/3 | I | Solid tumor with FGFR1 or FGFR2 gene amplification | Monotherapy/Single group | Safe and safe and with objective clinical response | NCT00979134 | 37 |
| II | Gastric, Esophageal, Breast, and lung SCC with FGFR1/2 amplification | Monotherapy/Single group | High anti-tumor activity in FGFR2 amplified gastric cancer and lower activity in FGFR1 amplified breast cancer | NCT01795768 | 36 | ||
| I/II | Advanced NSCLC | Docetaxel alone VS Docetaxel with concomitant AZD4547 | N/A | NCT01824901 | |||
| I/II | ER+ Breast Cancer patients progressed after NSAIs | AZD4547 with Anastrozole or Letrozole | N/A | NCT01791985 | |||
| II | ER+ Breast Cancer with FGFR1 polysomy or amplification | AZD4547 with Fulvestrant vs. Fulvestrant Alone | N/A | NCT01202591 | |||
| II/III | Lung SCC positive for FGFR1/2/3 | AZD4547 vs Docetaxel | N/A | NCT02154490* | |||
| II | Advanced cancer with FGFR1/2/3 mutation or translocation | Monotherapy/Single group | N/A | NCT02465060* | |||
| BGJ398 | FGFR1/2/3 | I | Advanced solid tumors with alterations of FGFR1/2/3 | Monotherapy/Single group | Safe and with objective clinical response | NCT01004224 | 33 |
| II | Recurrent Glioblastoma with amplification or translocation of FGFR1-TACC1, FGFR3-TACC-3 fusion and/or activating mutation in FGFR1/2/3 | Monotherapy/Single group | N/A | NCT01975701 | |||
| II | Head and Neck Cancer Patients with FGFR1/2/3 translocation, mutation, or amplification | Monotherapy/Single group | N/A | NCT02706691 | |||
| ASP5878 | FGFR1/2/3/4 | I | Advanced solid Tumors | Monotherapy/Single group | N/A | NCT02038673 | |
| ARQ087 | FGFR1/2/3 | I/II | Advanced solid Tumors with FGFR genetic alterations | Monotherapy/Single group | Safe and with objective clinical response | NCT01752920 | 35 |
| BAY1163877 | FGFR1/2/3/4 | I | Advanced solid tumors with high FGFR expression | Monotherapy/Single group | N/A | NCT02592785 | |
| Debio1347 | FGFR1/2/3 | I/II | Advanced solid tumor with FGFR1/2/3 alteration | Monotherapy/Single group | N/A | NCT01948297 | |
| LY2874455 | FGFR1/2/3/4 | I | Advanced cancers | Monotherapy/Single group | N/A | NCT01212107 | |
| INCB054828 | FGFR1/2/3 | II | Myeloid/lymphoid neoplasms with FGFR1 rearrangement | Monotherapy/Single group | N/A | NCT03011372 | |
| JNJ-42756493 | Pan-FGFR | I/II/III | Advanced solid tumors with FGFR alterations | Monotherapy/Single group | Phase I: Safe and with objective clinical response | NCT01703481* | 34 |
| PRN1371 | FGFR1/2/3/4 | I | Advanced solid tumors, expansion cohort in patients with FGFR 1/2/3/4 genetic alterations | Monotherapy/Single group | N/A | NCT02608125 | |
| TAS-120 | FGFR1/2/3/4 | I/II | Advanced solid tumors | Monotherapy/Single group | N/A | NCT02052778 |
*
Multiple arms include anti-FGFR treatment cohort; NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma; FGFR, fibroblast growth factor receptor